• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Proqr Therapeutics (NQ: PRQR )

    1.845 +0.005 (+0.27%)
    Streaming Delayed Price Updated: 2:37 PM EDT, Sep 10, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 29,976
    Open 1.820
    Bid (Size) 1.840 (4)
    Ask (Size) 1.850 (4)
    Prev. Close 1.840
    Today's Range 1.820 - 1.900
    52wk Range 1.110 - 3.290
    Shares Outstanding 80,817,079
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    PRQR Stock Earnings: ProQR Therapeutics Beats EPS, Misses Revenue for Q2 2024
    PRQR stock results show that ProQR Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
    Via InvestorPlace
    ProQR Announces Second Quarter 2024 Operating and Financial Results
    From ProQR Therapeutics N.V.
    Via GlobeNewswire

    Performance

    YTD
    -11.08%
    -11.08%
    1 Month
    -7.75%
    -7.75%
    3 Month
    +1.93%
    +1.93%
    6 Month
    -8.66%
    -8.66%
    1 Year
    +15.31%
    +15.31%

    More News

    Read More
    ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit
    From ProQR Therapeutics N.V.
    Via GlobeNewswire
    ProQR Announces First Quarter 2024 Operating and Financial Results
    From ProQR Therapeutics N.V.
    Via GlobeNewswire
    4 Analysts Have This to Say About ProQR Therapeutics
    Via Benzinga
    ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases
    From ProQR Therapeutics N.V.
    Via GlobeNewswire
    ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
    From ProQR Therapeutics N.V.
    Via GlobeNewswire
    ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
    From ProQR Therapeutics N.V.
    Via GlobeNewswire
    ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
    From ProQR Therapeutics N.V.
    Via GlobeNewswire
    ProQR Announces Year End 2023 Operating and Financial Results
    From ProQR Therapeutics N.V.
    Via GlobeNewswire
    ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
    From ProQR Therapeutics N.V.
    Via GlobeNewswire
    ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
    From ProQR Therapeutics N.V.
    Via GlobeNewswire
    Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Why Airspan Networks Shares Are Trading Higher By Over 380%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
    From ProQR Therapeutics N.V.
    Via GlobeNewswire
    ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
    From ProQR Therapeutics N.V.
    Via GlobeNewswire
    US Stocks Lower; Dow Falls Over 50 Points
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Bluebird Bio To Rally Around 267%? Here Are 10 Top Analyst Forecasts For Wednesday
    Via Benzinga
    ProQR Announces Third Quarter 2023 Operating and Financial Results
    From ProQR Therapeutics N.V.
    Via GlobeNewswire
    ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing
    From ProQR Therapeutics N.V.
    Via GlobeNewswire
    ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference
    From ProQR Therapeutics N.V.
    Via GlobeNewswire
    ProQR Therapeutics Provides Update on Ophthalmic Assets
    From ProQR Therapeutics N.V.
    Via GlobeNewswire
    ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference
    From ProQR Therapeutics N.V.
    Via GlobeNewswire
    ProQR Announces Second Quarter 2023 Operating and Financial Results
    From ProQR Therapeutics N.V.
    Via GlobeNewswire
    ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets
    From ProQR Therapeutics N.V.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.